MOR Stock Overview
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||€19.63|
|52 Week High||€72.84|
|52 Week Low||€16.45|
|1 Month Change||-17.76%|
|3 Month Change||-18.17%|
|1 Year Change||-72.22%|
|3 Year Change||-79.05%|
|5 Year Change||-69.98%|
|Change since IPO||190.82%|
Recent News & Updates
|MOR||DE Biotechs||DE Market|
Return vs Industry: MOR underperformed the German Biotechs industry which returned -31.6% over the past year.
Return vs Market: MOR underperformed the German Market which returned -13.3% over the past year.
|MOR Average Weekly Movement||8.2%|
|Biotechs Industry Average Movement||8.2%|
|Market Average Movement||6.3%|
|10% most volatile stocks in DE Market||10.7%|
|10% least volatile stocks in DE Market||3.5%|
Stable Share Price: MOR is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: MOR's weekly volatility (8%) has been stable over the past year.
About the Company
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2.
MorphoSys Fundamentals Summary
|MOR fundamental statistics|
Is MOR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MOR income statement (TTM)|
|Cost of Revenue||€35.04m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 03, 2022
|Earnings per share (EPS)||-17.44|
|Net Profit Margin||-342.46%|
How did MOR perform over the long term?See historical performance and comparison
Is MorphoSys undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MOR's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate MOR's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: MOR is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: MOR is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MOR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MOR is overvalued based on its PB Ratio (4.7x) compared to the DE Biotechs industry average (1.5x).
How is MorphoSys forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MOR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MOR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MOR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MOR's revenue (30.2% per year) is forecast to grow faster than the German market (4.8% per year).
High Growth Revenue: MOR's revenue (30.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MOR is forecast to be unprofitable in 3 years.
How has MorphoSys performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MOR is currently unprofitable.
Growing Profit Margin: MOR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MOR is unprofitable, and losses have increased over the past 5 years at a rate of 33.2% per year.
Accelerating Growth: Unable to compare MOR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MOR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: MOR has a negative Return on Equity (-420.14%), as it is currently unprofitable.
How is MorphoSys's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: MOR's short term assets (€1.0B) exceed its short term liabilities (€239.0M).
Long Term Liabilities: MOR's short term assets (€1.0B) do not cover its long term liabilities (€2.1B).
Debt to Equity History and Analysis
Debt Level: MOR has more cash than its total debt.
Reducing Debt: MOR's debt to equity ratio has increased from 0.05% to 202% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MOR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MOR has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 41.7% each year
What is MorphoSys's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MOR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MOR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MOR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MOR's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MOR has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jean-Paul Kress (56 yo)
Dr. Jean-Paul Kress, M.D. has been the Chief Executive Officer of MorphoSys AG since September 1, 2019 and has been its Management Board Member since 2019 and serves as its Chairman of Management Board and...
CEO Compensation Analysis
Compensation vs Market: Jean-Paul's total compensation ($USD2.04M) is above average for companies of similar size in the German market ($USD1.30M).
Compensation vs Earnings: Jean-Paul's compensation has been consistent with company performance over the past year.
Experienced Management: MOR's management team is considered experienced (2.3 years average tenure).
Experienced Board: MOR's board of directors are considered experienced (5.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.2%.
MorphoSys AG's employee growth, exchange listings and data sources
- Name: MorphoSys AG
- Ticker: MOR
- Exchange: XTRA
- Founded: 1992
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €670.341m
- Shares outstanding: 34.15m
- Website: https://www.morphosys.com
Number of Employees
- MorphoSys AG
- Semmelweisstrasse 7
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/20 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.